Artlegia (olokizumab) / R-Pharm 
Welcome,         Profile    Billing    Logout  
 14 Diseases   3 Trials   3 Trials   139 News 
3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Artlegia (olokizumab) / R-Pharm
R-Pharm_COVID_19: Cromos Pharma Supports R-Pharm in Initiation of a Global Program to Test Two of its Leading Candidates in Patients with Severe COVID-19 Infection. First Patients Have Been Recruited

Not yet recruiting
3
180
US
olokizumab (CDP-6038) - R-Pharm
R-Pharm
Severe COVID-19
 
 
RESET, NCT05187793: Study of Efficacy of Different Treatment Regimens of Olokizumab

Active, not recruiting
3
198
RoW
Olokizumab, Standard therapy
R-Pharm, Federal Budget Institution of Science "Central Research Institute of Epidemiology" of the Rospotrebnadzor, Group of companies Medsi, JSС
COVID-19
10/22
04/23
NCT06440746: Efficacy and Safety of Olokizumab in Patients With Progressive Fibrosing Interstitial Lung Diseases

Recruiting
2/3
116
RoW
Subcutaneous (SC) injections of OKZ 64 milligrams (mg) every 4 weeks (q4w), one injection of 0.4 millilitre (mL), Artlegia, SC injections of Placebo every 4 weeks (q4w), one injection of 0.4 mL
R-Pharm International, LLC, R-Pharm, Exacte Labs LLC, Data Management 365, Keystat, LLC
Lung Diseases, Interstitial
06/26
12/26

Download Options